Patents Examined by Heidi Reese
  • Patent number: 10385037
    Abstract: Provided are 4?-O substituted isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: August 20, 2019
    Assignee: Celgene Corporation
    Inventors: Alexander L. Ruchelman, George W. Muller, Hon-Wah Man, Roger Shen-Chu Chen
  • Patent number: 10385024
    Abstract: The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: August 20, 2019
    Assignee: ARDELYX, INC.
    Inventors: Noah Bell, Christopher Carreras, Dominique Charmot, Tao Chen, Michael Leadbetter, Jeffrey Jacobs, Jason Lewis
  • Patent number: 10383943
    Abstract: Compositions and methods for the use thereof for the treatment of cancer in a subject in need thereof comprising administering to the subject an effective amount of a composition comprising an anticancer composition comprising a antineoplastic compound and a conjugated targeting moiety with or without a chemical linker. In certain aspects the antineoplastic compound is a platin and the conjugated targeting moiety is an amino acid.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: August 20, 2019
    Assignee: South Dakota Board of Regents
    Inventors: Hemachand Tummala, Pratik Muley
  • Patent number: 10377766
    Abstract: The invention relates to heterocyclic compounds with benzo[c]coumarin structures and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: August 13, 2019
    Assignee: Merck Patent GmbH
    Inventors: Amir Hossain Parham, Teresa Mujica-Fernaud, Thomas Eberle, Anja Jatsch, Jonas Valentin Kroeber, Tobias Grossmann
  • Patent number: 10377714
    Abstract: A trans-isomeric compound of formula (I) below or a pharmaceutically acceptable salt thereof: in which R1 is C1-C5 alkyl or C3-C5 cycloalkyl and the trans-isomeric compound has a trans:cis ratio of at least 70:30. Further disclosed is a method for preparing the trans-isomeric compound.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: August 13, 2019
    Assignee: TaiGen Biotechnology Co., Ltd.
    Inventors: Shan-Yen Chou, Wen-Chang Chen, Chi-Feng Yen, Han-Pei Hsu, Ming-Chu Hsu, Chu-Chung Lin
  • Patent number: 10377965
    Abstract: The present invention relates to a delivery system based on photosensitive acetal or ketal compounds capable of liberating upon exposure to light an active volatile carbonyl compound in a controlled manner from a surface into the surrounding. The delivery system can be used to release active substances such as flavors, fragrances, malodor counteractants, insect attractants or insect repellents. The invention also relates to the use of said acetal or ketal compounds in perfumery, as well as in perfuming compositions or perfumed consumer articles.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: August 13, 2019
    Assignee: Firmenich SA
    Inventor: Andreas Herrmann
  • Patent number: 10377730
    Abstract: The problem of the present invention is to provide a useful prodrug compound of a naphthofuran compound. The present invention relates to a compound represented by the formula (IA): [wherein each symbol is as described in the DESCRIPTION] or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: August 13, 2019
    Assignees: Kyoto Pharmaceutical Industries, Ltd., Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Yoshinobu Yoshimura, Masayasu Kasai, Yoshimichi Shoji, Shigemitsu Takeda
  • Patent number: 10377749
    Abstract: The present invention addresses the problem of providing a purification method for a 5-(thiazol-4-yl)indolin-2-one derivative that is useful as a medication. The present invention provides a purification method for a compound represented by formula (1) (in the formula, each n is independently 2, 3, 4, 5, or 6, R1 and R2 are identical or different and each independently represent a C1-6 alkyl group, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, and R13 each represent a hydrogen atom, a C1-6 alkyl group, an aryl group, or a heteroaryl group), or a geometric isomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof. The purification method includes a purification step performed using a solid-phase support adsorbent in the presence of a purification solvent.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: August 13, 2019
    Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Akihito Nonoyama, Kazuki Hashimoto
  • Patent number: 10376488
    Abstract: Disclosed is a method for wound healing comprising administering a subject in need thereof a therapeutically effective amount of a flavonoid compound, wherein the compound is preferably nonglycosylated flavone. Specifically, the present invention can be used for treating skin symptoms of a trauma, a burn, a scald and a chronic wound, and can be particularly used for healing a wound of a diabetes patient.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: August 13, 2019
    Assignee: ONENESS BIOTECH CO., LTD
    Inventors: Wei-Luen Chang, Mo-Chi Cheng
  • Patent number: 10370355
    Abstract: The present invention relates to tetrahydroisoquinoline derivatives according to formula (I), wherein G represents a fused heterocyclic system selected from the groups represented by formula (G1), (G2), (G3), (G4), (G5), and (G6), which are Positive Allosteric Modulators of D1 and accordingly of benefit as pharmaceutical agents for the treatment of diseases in which D1 receptors play a role.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: August 6, 2019
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Ali Ates, Eric Jnoff, Laurent Provins, Anne Valade, Adrian Hall
  • Patent number: 10370406
    Abstract: SCY-078 is a glucan synthase inhibitor with antimicrobial activity. Novel salts and polymorph forms of SCY-078 are disclosed herein. The disclosure also relates to pharmaceutical compositions, methods of use, and methods of preparing the novel salts and polymorphs of SCY-078.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: August 6, 2019
    Assignee: SCYNEXIS, INC.
    Inventor: Yi Zhang
  • Patent number: 10364230
    Abstract: Disclosed are chromene-2 derivatives and the use thereof in the treatment of fibrosis. Specifically, disclosed are the derivatives of a compound having a main structure of 6,7-dimethoxy-chromenylium perchlorate (1) and pharmaceutical compositions, combinations and pharmaceutically suitable salts thereof for the treatment of fibrosis.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: July 30, 2019
    Assignee: ALTAY THERAPEUTICS, INC.
    Inventor: Osman Nidai Özes
  • Patent number: 10364263
    Abstract: Compounds having the following formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, D, E and R1 are as defined herein, are provided. Methods comprising the use of such compounds for the treatment of neurological disorders, such as pantothenate kinase-associated neurodegeneration, and pharmaceutical compositions containing such compounds, and their use in the treatment of neurological disorders, also are provided.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: July 30, 2019
    Assignee: Retrophin, Inc.
    Inventors: Maria Beconi, Daniel Elbaum, Steven Harper, Savina Malancona
  • Patent number: 10364240
    Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: July 30, 2019
    Assignee: ChemoCentryx. Inc.
    Inventors: Solomon Ungashe, John J. Wright, Andrew Pennell, Zheng Wei, Anita Melikian
  • Patent number: 10358445
    Abstract: The present invention relates to respiratory formulations comprising a compound of formula (I): and use of said compounds and compositions in treatment, for example in the treatment of an inflammatory disease or a respiratory disorder, in particular an inflammatory mediated and/or virally mediated respiratory disorder such as asthma and COPD or the treatment or prevention of viral infection, for example infection by influenza virus, rhinovirus or RSV. The invention also extends to certain novel compounds of formula (I).
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: July 23, 2019
    Assignee: RESPIVERT, LTD.
    Inventors: Peter John Murray, Stuart Thomas Onions, Jonathan Gareth Williams, Kevin Joly
  • Patent number: 10357481
    Abstract: The present invention is directed to substituted triazolo bicyclic compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: July 23, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Gregori J. Morriello, Lehua Chang, Ashley Forster, Yili Chen, Michael P. Dwyer, Zack Zhiqiang Guo, Ming Wang, Shimin Xu, Yingjian Bo, Jianmin Fu
  • Patent number: 10350178
    Abstract: Disclosed herein is a method of prevention of progression of a multiple sclerosis in a patient, comprising the administration of methylglyoxal bis(guanylhydrazone) (MGBG) to the patient in need thereof. Also disclosed herein is a method of prevention or reduction in severity of the initiation phase of autoimmune response in a patient having multiple sclerosis, comprising the administration of MGBG to the patient in need thereof.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: July 16, 2019
    Assignee: Pathologica LLC
    Inventors: Jeremy Blitzer, John McKearn
  • Patent number: 10350315
    Abstract: The present application provides quinoline-3-carboxamide compounds covalently linked to a label for use in the diagnosis of an inflammatory disease at local site. The above mentioned compounds can be used to detect or image accumulation of S100A9 in the body of a subject at sites of inflammation, using in vivo non-invasive molecular imaging techniques for the detection of said compounds. Accordingly, labeled quinoline-3-carboxamide compounds can be applied to evaluate the risk of a subject of developing an inflammatory disease and to follow the progress of the disease.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: July 16, 2019
    Assignee: Westfaelische Wihelms-Universitaet Muenster
    Inventors: Andreas Faust, Sven Hermann, Johannes Roth, Michael Schaefers, Thomas Vogl
  • Patent number: 10342770
    Abstract: Treatment of NAFLD and NASH by therapy with MBX-8025 or an MBX-8025 salt.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: July 9, 2019
    Assignee: CymaBay Therapeutics, Inc.
    Inventors: Brian Roberts, Xueyan Wang, Yun-Jung Choi, David Karpf, Robert Martin, Charles McWherter
  • Patent number: 10344043
    Abstract: The present document describes compounds resulting from the complexation of quaternary ammonium compounds with boric acid and/or its derivatives, and methods of making the same, and methods of using the same for the treatment of pathogenic infections.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: July 9, 2019
    Inventors: Tien Canh Le, Giuliano Lafrenière Di Fruscia